부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.exphem.2004.05.028 Byline: Deborah L. French (a), Steven Fruchtman (a), W. Beau Mitchell (a), Barry S. Coller (b), Hava Peretz (c) Abstract: Assessment of donor chimerism is becoming increasingly important in patients undergoing reduced-intensity conditioning (RIC) allogeneic bone marrow transplants, due to the possibility of mixed chimeras. This regimen has been used successfully for patients with leukemia and genetic disorders with donor chimerism occurring in the myeloid, lymphoid, and/or erythroid lineages. Less toxic RIC expands the potential application of stem cell transplants to patients with nonmalignant disorders of hematopoiesis, such as the severe form of Glanzmann thrombasthenia, who previously were not considered suitable candidates based on risk-benefit analysis. To assess megakaryocyte/platelet chimerism after stem cell transplantation conducted with RIC, we used restriction fragment length polymorphism (RFLP) and sequence analyses of the HPA-3 polymorphism in the megakaryocyte/platelet-specific glycoprotein [alpha]IIb. In this study we show that at 23 weeks post-RIC, a leukemia patient acquired the HPA-3 donor phenotype at the DNA and platelet RNA levels. Author Affiliation: (a) Departments of Medicine and Pediatrics, Mount Sinai School of Medicine, New York, NY, USA; (b) Blood and Vascular Biology Laboratory, Rockefeller University, New York, NY, USA; (c) Clinical Biochemistry Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Article History: Received 29 October 2003; Revised 20 May 2004; Accepted 26 May 2004